Cargando…

Delayed Onset of Symptomatic Dermatographism following COVID-19 mRNA Booster

Detalles Bibliográficos
Autor principal:	Co, Margaret
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Mosby, Inc. 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9895912/ http://dx.doi.org/10.1016/j.jaci.2022.12.521

Ejemplares similares

COVID-19 Vaccine Booster-Induced Dermatographism
por: Amjad, Mohammad A, et al.
Publicado: (2022)

Unmasking symptomatic dermatographism in the time of COVID-19
por: Wong, Katelyn H, et al.
Publicado: (2020)

Dermatographism with vulvar symptoms
por: Rivera, Sydney, et al.
Publicado: (2021)

Woman with pruritic rash and dermatographism
por: Malcolm, Trent R., et al.
Publicado: (2022)

Delayed onset urticaria and symptomatic dermographism following COVID‐19 booster vaccination: A case series
por: Drivenes, Jakob Lillemoen, et al.
Publicado: (2022)

Imaging of Myocarditis Following mRNA COVID-19 Booster Vaccination
por: Sanchez Tijmes, Felipe, et al.
Publicado: (2022)

Reactogenicity to the mRNA-1273 Booster According to Previous mRNA COVID-19 Vaccination
por: Parés-Badell, Oleguer, et al.
Publicado: (2022)

Acute panuveitis after COVID-19 mRNA booster vaccination following cataract surgery
por: Kung, Timothy-Paul H., et al.
Publicado: (2022)

Heterologous mRNA-based COVID-19 booster strategies: Comment
por: Yasri, Sora, et al.
Publicado: (2023)

Durability of immune responses to mRNA booster vaccination against COVID-19
por: Arunachalam, Prabhu S., et al.
Publicado: (2023)

Fourth-dose boosters with COVID-19 mRNA vaccines well tolerated
Publicado: (2022)

Reactogenicity of Simultaneous COVID-19 mRNA Booster and Influenza Vaccination in the US
por: Hause, Anne M., et al.
Publicado: (2022)

Adult-onset Still's disease following mRNA COVID-19 vaccination
por: Sharabi, Amir, et al.
Publicado: (2021)

Acute-onset dacryoadenitis following immunisation with mRNA COVID-19 vaccine
por: Murphy, Treasa, et al.
Publicado: (2022)

New-onset MOGAD after first-dose SARS-CoV-2 mRNA vaccination with relapse following SARS-CoV-2 mRNA booster
por: Arismendez, Alan A., et al.
Publicado: (2023)

Anaphylaxis induced by mRNA COVID-19 vaccines: follow-up and booster dose after previous desensitization
por: AlOtaibi, Ibtihal, et al.
Publicado: (2023)

Immune Thrombocytopenia Following Booster Dose of the Moderna mRNA-1273 Vaccine
por: Breetz, Katherine A, et al.
Publicado: (2022)

Author reply to “Heterologous mRNA-based COVID-19 booster strategies: Comment”
por: Das, Rituparna, et al.
Publicado: (2023)

Abstract #1403045: Thyroiditis Post COVID-19 mRNA Booster Dose Vaccination
por: Seow, Cherng Jye
Publicado: (2023)

mRNA-based COVID-19 Vaccines Booster Dose: Benefits, Risks, and Coverage
por: Nashwan, Abdulqadir J., et al.
Publicado: (2022)

Acute Pericarditis Post mRNA-1273 COVID Vaccine Booster
por: Singh, Arminder, et al.
Publicado: (2022)

New‐onset vitiligo following mRNA‐1273 (Moderna) COVID‐19 vaccination
por: Kaminetsky, Joshua, et al.
Publicado: (2021)

Myocarditis following COVID‐19 mRNA (mRNA‐1273) vaccination
por: Chellapandian, Suresh Babu, et al.
Publicado: (2022)

Posterior Reversible Encephalopathy Syndrome Onset Within 24 Hours Following Moderna mRNA Booster COVID-19 Vaccination: Vaccine Adverse Event Vs. Hypertension?
por: McCullough, Jocelyn, et al.
Publicado: (2022)

Waning Immunity Against XBB.1.5 Following Bivalent mRNA Boosters
por: Lasrado, Ninaad, et al.
Publicado: (2023)

Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine
Publicado: (2023)

Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine
por: Goh, Yun Shan, et al.
Publicado: (2022)

mRNA-based COVID-19 booster vaccination is highly effective and cost-effective in Australia
por: Li, Rui, et al.
Publicado: (2023)

Emerging heterologous mRNA-based booster strategies within the COVID-19 vaccine landscape
por: Das, Rituparna, et al.
Publicado: (2023)

Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes
por: Grewal, Ramandip, et al.
Publicado: (2023)

mRNA COVID-19 vaccine booster fosters B- and T-cell responses in immunocompromised patients
por: Azzolini, Elena, et al.
Publicado: (2022)

What a second booster dose of mRNA COVID-19 vaccines tells us
por: Loubet, Paul, et al.
Publicado: (2022)

Severe Acute Myocarditis after the Third (Booster) Dose of mRNA COVID-19 Vaccination
por: Mengesha, Bethlehem, et al.
Publicado: (2022)

Side Effects after mRNA COVID-19 Vaccine as a Booster in Health Workers
por: Pakki, Temmasonge Radi, et al.
Publicado: (2022)

The Effects of an mRNA Covid-19 Vaccine Booster on Immune Responses in Cancer-Bearing Veterans
por: Frankel, Arthur E., et al.
Publicado: (2022)

Delayed presentation of biopsy-proven eosinophilic myocarditis following COVID-19 mRNA vaccine
por: Janga, Chaitra, et al.
Publicado: (2023)

Enhanced SARS-CoV-2 IgG durability following COVID-19 mRNA booster vaccination and comparison of BNT162b2 with mRNA-1273
por: Ailsworth, Samuel M., et al.
Publicado: (2023)

Symptomatic SARS-CoV-2 breakthrough with delta variant after 3rd mRNA vaccine shot (booster)
por: Schildgen, Verena, et al.
Publicado: (2022)

Frequent Onsets of Cellulitis in Lower Limbs with Lymphedema Following COVID-19 mRNA Vaccination
por: Okazaki, Tatsuma, et al.
Publicado: (2022)

New Onset of Eosinophilic Granulomatosis with Polyangiitis Following mRNA-Based COVID-19 Vaccine
por: Nappi, Emanuele, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1rmsh6rb6129mkt84mgru50qsn